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Flavonoid intake is associated with lower mortality
in the Danish Diet Cancer and Health Cohort
Nicola P. Bondonno 1,2,12, Frederik Dalgaard 3,12, Cecilie Kyrø 4, Kevin Murray 5,
Catherine P. Bondonno 1,2, Joshua R. Lewis 1,2, Kevin D. Croft 1, Gunnar Gislason3,6,7,
Augustin Scalbert 8, Aedin Cassidy 9, Anne Tjønneland 4, Kim Overvad 10,11 &
Jonathan M. Hodgson 1,2
Flavonoids, plant-derived polyphenolic compounds, have been linked with health benefits.
However, evidence from observational studies is incomplete; studies on cancer mortality are
scarce and moderating effects of lifestyle risk factors for early mortality are unknown. In this
prospective cohort study including 56,048 participants of the Danish Diet, Cancer, and
Health cohort crosslinked with Danish nationwide registries and followed for 23 years, there
are 14,083 deaths. A moderate habitual intake of flavonoids is inversely associated with all-
cause, cardiovascular- and cancer-related mortality. This strong association plateaus at
intakes of approximately 500mg/day. Furthermore, the inverse associations between total
flavonoid intake and mortality outcomes are stronger and more linear in smokers than in non-
smokers, as well as in heavy (>20 g/d) vs. low-moderate (<20 g/d) alcohol consumers.
These findings highlight the potential to reduce mortality through recommendations to
increase intakes of flavonoid-rich foods, particularly in smokers and high alcohol consumers.
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Fruit and vegetable intakes are associated with a lower risk ofcardiovascular disease (CVD), cancer, and all-cause mor-tality, with an estimated 7.8 million premature deaths
worldwide in 2013 attributable to a fruit and vegetable intake
below 800 g/day1. These benefits are likely due in part to flavo-
noids, a class of polyphenolic compounds found in abundance in
plant-derived foods and beverages such as fruits, vegetables, dark
chocolate, tea, and red wine2. Flavonoids are categorized into six
main subclasses based on their chemical structure: flavonols,
flavan-3-ols, flavanones, flavones, anthocyanins, and isoflavones.
Structural differences bring about variations in metabolism and
bioactivity3, which may result in varying effects on health
outcomes4.
Evidence for the potential health benefits of flavonoids comes
from epidemiological studies, short-term randomized con-
trolled trials, and preclinical studies. Short-term clinical trials
have demonstrated that flavonoid compounds and flavonoid-
rich foods improve surrogate measurements of CVD risk5
Results from preclinical studies suggest that flavonoids may also
modulate the risk of cancer6. Evidence from observational
studies is incomplete; studies on cancer mortality are scarce and
additional research is necessary to establish the specific role of
flavonoid subclasses and to determine the dose of total and
specific flavonoids required to achieve maximum benefit7.
Additionally, emerging evidence suggests that flavonoids may
afford greater protection to those with lifestyle habits placing
them at risk of early mortality8. Flavonoids may protect against
some of the detrimental effects that these factors have on nitric
oxide bioavailability, endothelial function, blood pressure,
inflammation, blood lipids, platelet function, and/or
thrombosis9.
The primary aim of this study was to investigate the association
of total flavonoid and flavonoid subclass intakes with all-cause,
CVD-related, and cancer-related mortality in 56,048 participants
of the Danish Diet, Cancer, and Health cohort. We demonstrate
that an achievable dietary intake of total and individual flavonoid
subclasses is associated with a lower risk of all-cause, CVD-
related, and cancer-related mortality. Secondary aims were to
investigate whether these associations differed according to the
presence of modifiable lifestyle risk factors. We demonstrate that
inverse associations are strongest for current smokers and indi-
viduals with high alcohol consumption.
Results
Baseline characteristics. In this population of 56,048 Danish
citizens, with a median [IQR] age of 56 [52–60] years at entry,
14,083 died from any cause during 1,085,186 person-years of
follow-up. Of the 52,492 participants without CVD at baseline,
4065 died of CVD and of the 55,801 participants without cancer
at baseline, 6299 died of cancer. The baseline characteristics of
the study population overall and stratified by total flavonoid
intake quintiles are shown in Table 1. The median [IQR] total
flavonoid intake was 494 [286–804] mg/d and the distribution
was skewed-right. Pearson’s correlations between flavonoid
subclass intakes ranged from 0.97 for the flavonols and flavanol
monomers to 0.01 for the flavanol monomers and the flava-
nones (Supplementary Table 1). Compared to participants in
the lowest quintile of total flavonoid intake, those in the highest
quintile tended to have a lower BMI and be more physically
active, and were less likely to be current smokers and more
likely to be female, have a higher level of education, and a
higher income. They also tended to have a lower prevalence of
heart failure, ischemic heart disease, stroke, and COPD. Parti-
cipants with higher flavonoid intake consumed more dietary
fiber and less red meat and processed meat.
Total and flavonoid subclasses and all-cause mortality. For total
flavonoids and all flavonoid subclasses, the test of nonlinearity was
statistically significant (P-nonlinearity < 0.001). Evidence of a
threshold effect for the association between total flavonoid intake
and all-cause mortality can be seen in Fig. 1, where the inverse
relationship plateaued beyond intakes of approximately 500mg/d.
A similar association was seen for all flavonoid subclasses, with the
threshold occurring at varying levels of intake, except the flavone
and flavanone subclasses, which were slightly U-shaped (Fig. 2).
HRs for quintiles of total flavonoid and flavonoid subclass intakes
are shown in Table 2. For total flavonoid intake, after multivariable
adjustments (model 2), participants in the second and third
quintile were at a lower risk of all-cause mortality [HR (95% CI),
Q2: 0.88 (0.85, 0.91) and Q3:0.83 (0.80, 0.86)]. At higher levels of
the exposure, the HR remained constant. In general, adjustments
for potential lifestyle and dietary confounders (model 3) slightly
attenuated the association and HRs for all flavonoid subclasses
were not substantially lower beyond quintile 3.
Total and flavonoid subclasses and cause-specific mortality.
Intakes above those in quintile 1 for total flavonoids and all fla-
vonoid subclasses were associated with a lower risk of both CVD-
and cancer-related mortality after adjustment for potential life-
style and dietary confounders. For CVD-related mortality, the
association plateaued beyond intakes of approximately 500 mg/d
of total flavonoids (Fig. 1) and in general, the associations were
stable beyond quintile 3 for any subclass (Table 3 and Supple-
mentary Fig. 1). For cancer-related mortality, the association
plateaued at approximately 1000 mg/d of total flavonoids (Fig. 1)
and for the flavonol, flavanol oligo+ polymer subclasses, lower
HRs were observed until quintile 5 (Table 4 and Supplementary
Fig. 2).
Stratified analyses. The associations between flavonoid intake
and both all-cause and cause-specific mortality differed according
to smoking status, alcohol intake, and BMI, but not by sex, level
of physical activity, or presence of prevalent diabetes.
As there was no difference in association between flavonoid
intake and mortality for never vs. former smokers, these were
collapsed into one subgroup. The inverse association between
total flavonoid intake and both all-cause and cause-specific
mortality was stronger in smokers than in non-smokers as well as
in those who consumed >20 g/d of alcohol compared to those
who consumed ≤20 g/d of alcohol (Fig. 3 and Supplementary
Figs. 3 and 4). These benefits appeared extend to higher doses of
up to 1000–2000 mg/d. Evidence of a dose–response association
can be seen in Supplementary Fig. 5, where the association
between total flavonoid intake and both all-cause and cancer-
related mortality tended to stronger at higher smoking intensity
(assessed by pack-years) and alcohol intake (g/d). Similar,
although less clear, interactions between flavonoid intake and
both smoking intensity and alcohol intake were seen for CVD-
related mortality.
In general, the lower risk of mortality associated with higher
flavonoid intake tended to be weaker in obese (BMI > 30)
participants in comparison to normal/overweight (18.5 > BMI ≤
30) participants (Fig. 3 and Supplementary Fig. 5).
Sensitivity analyses. Neither including energy intake in model
2, nor removing hypertension, hypercholesterolemia, and pre-
valent diseases from model 2, or adjusting for medication use
substantively altered the hazard ratios (Supplementary Table 2).
Excluding all participants with comorbidities at baseline (n= 5
492) marginally strengthened the relationship of total and
individual flavonoid subclass intake with all-cause mortality
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(Supplementary Table 2). When stratifying by tertiles of total
fruit and vegetable intake, evidence of an association between
total flavonoid intake and all-cause mortality remained
amongst participants in the highest intake tertile (Supplemen-
tary Table 3). There was no association between total flavonoid
intake and our falsification endpoint; a burn or foreign object
[n= 3 020; HR (95%CI) for Q5 vs Q1: 1.01 (0.92, 1.12); Sup-
plementary Table 4].
Discussion
There is great potential to improve population health through
improved dietary behaviors, with tailored recommendations
focusing on specific dietary components and population sub-
groups. In this prospective cohort study of 56,048 Danes, we
provide evidence that an achievable dietary intake of total and
individual flavonoid subclasses is associated with a lower risk of
all-cause, CVD-related, and cancer-related mortality. Our results
Table 1 Baseline characteristics of study population
Total population
n= 56 048
Total flavonoid intake quintiles
1
n= 11 210
2
n= 11 209
3
n= 11 210
4
n= 11 209
5
n= 11 210
Total flavonoid intake (g/d) 494 [286–804] 173 [127–212] 320 [286–356] 494 [441–548] 726 [659–804] 1201 [1024–1435]
Sex (male) 26666 (47.6) 6477 (57.8) 5740 (51.2) 5340 (47.6) 4996 (44.6) 4113 (36.7)
Age (years) 56 [52–60] 56 [52–60] 56 [52–60] 56 [52–60] 56 [52–60] 55 [52–60]
BMI (kg/m2) 25.5 [23.3–28.2] 26.1 [23.8–28.9] 25.9 [23.6–28.5] 25.6 [23.3–28.3] 25.3 [23.2–27.9] 24.9 [22.7–27.4]
MET score 56 [37–85] 51 [32–78] 56 [36–84] 58 [38–85] 58 [39–87] 60 [40–89]
Smoking status
Never 19666 (35.1) 2722 (24.3) 3743 (33.4) 3996 (35.6) 4461 (39.8) 4744 (42.3)
Former 16153 (28.8) 2695 (24.0) 3033 (27.1) 3266 (29.1) 3597 (32.1) 3562 (31.8)
Current 20229 (36.1) 5793 (51.7) 4433 (39.5) 3948 (35.2) 3151 (28.1) 2904 (25.9)
Education: ≤7 years 18466 (32.9) 5128 (45.7) 4268 (38.1) 3609 (32.2) 3031 (27.0) 2430 (21.7)
8–10 years 25817 (46.1) 4891 (43.6) 5263 (47.0) 5341 (47.6) 5317 (47.4) 5005 (44.6)
≥11 years 11737 (20.9) 1185 (10.6) 1674 (14.9) 2256 (20.1) 2854 (25.5) 3768 (33.6)
Household income
(DKK/year)
≤394 700 13919 (24.8) 3349 (29.9) 2749 (24.5) 2718 (24.2) 2581 (23.0) 2522 (22.5)
394 701–570 930 14018 (25.0) 3271 (29.2) 3003 (26.8) 2717 (24.2) 2603 (23.2) 2424 (21.6)
570 931–758 297 14054 (25.1) 2916 (26.0) 3034 (27.1) 2900 (25.9) 2621 (23.4) 2583 (23.0)
>758 297 14057 (25.1) 1674 (14.9) 2423 (21.6) 2875 (25.6) 3404 (30.4) 3681 (32.8)
Hypertensive 9148 (16.3) 1815 (16.2) 1860 (16.6) 1866 (16.6) 1823 (16.3) 1784 (15.9)
Hypercholesterolemic 4193 (7.5) 915 (8.2) 831 (7.4) 853 (7.6) 857 (7.6) 737 (6.6)
Diabetes 1182 (2.1) 279 (2.5) 221 (2.0) 254 (2.3) 217 (1.9) 211 (1.9)
Heart failure 220 (0.4) 56 (0.5) 54 (0.5) 39 (0.3) 40 (0.4) 31 0.3)
Atrial fibrillation 451 (0.8) 95 (0.8) 83 (0.7) 96 (0.9) 78 (0.7) 99 (0.9)
IHD 2200 (3.9) 586 (5.2) 423 (3.8) 438 (3.9) 400 (3.6) 353 (3.1)
PAD 498 (0.9) 171 (1.5) 114 (1.0) 84 (0.7) 61 (0.5) 68 (0.6)
Stroke 787 (1.4) 220 (2.0) 151 (1.3) 147 (1.3) 133 (1.2) 136 (1.2)
COPD 858 (1.5) 223 (2.0) 189 (1.7) 157 (1.4) 155 (1.4) 134 (1.2)
CKD 204 (0.4) 43 (0.4) 33 (0.3) 44 (0.4) 42 (0.4) 42 (0.4)
Cancer 247 (0.4) 55 (0.5) 42 (0.4) 61 0.5) 33 (0.3) 56 (0.5)
Insulin treated 381 (0.7) 78 (0.7) 65 (0.6) 86 (0.8) 81 (0.7) 71 (0.6)
Antihypertensive 6904 (12.3) 1363 (12.2) 1422 (12.7) 1407 (12.6) 1363 (12.2) 1349 (12.0)
Statin 1074 (1.9) 262 (2.3) 211 (1.9) 221 (2.0) 212 (1.9) 168 (1.5)
HRT
Never 15972 (54.4) 2606 (55.1) 3049 (55.8) 3268 (55.7) 3271 (52.6) 3778 (53.2)
Current 8825 (30.0) 1295 (27.4) 1572 (28.7) 1698 (28.9) 2001 (32.2) 2259 (31.8)
Former 4553 (15.5) 823 (17.4) 844 (15.4) 897 (15.3) 935 (15.0) 1054 (14.9)
NSAIDs excluding aspirin 18161 (32.6) 3543 (31.9) 3530 (31.7) 3642 (32.7) 3640 (32.6) 3806 (34.2)
Aspirin 7097 (12.7) 1392 (12.4) 1366 (12.2) 1437 (12.8) 1395 (12.4) 1507 (13.4)
Energy (kj) 9500
[7858–11368]
8610
[7026–10387]
9262
[7717–11000]
9752
[8139–11586]
9938
[8321–11834]
9928
[8258–11887]
Saturated FA (g/d) 31 [24–40] 29 [23–38] 31 [24–39] 32 [25–40] 32 [25–41] 32 [24–41]
Polyunsaturated FA (g/d) 13 [10–17] 12 [9–16] 13 [10–17] 14 [10–18] 14 [11–18] 14 [10–18]
Monounsaturated FA (g/d) 27 [21–35] 26 [20–34] 27 [21–35] 28 [22–35] 28 [22–35] 27 [21–34]
Total fish intake (g/d) 38 [25–55] 33 [22–49] 38 [25–54] 40 [27–57] 41 [28–59] 40 [27–57]
Red meat intake (g/d) 78 [57–107] 80 [58–108] 81 [59–110] 80 [58–110] 78 [57–107] 72 [52–100]
Processed meat intake (g/d) 25 [14–40] 29 [17–45] 26 [16–42] 25 [14–40] 23 [14–38] 21 [12–34]
Dietary fiber intake (g/d) 20 [16–25] 17 [13–20] 19 [16–23] 21 [17–25] 22 [18–27] 23 [19–29]
Vegetable intake (g/d) 161 [105–231] 114 [71–170] 150 [99–211] 168 [113–235] 184 [127–254] 196 [135–272]
Fruit intake (g/d) 171 [95–281] 87 [44–140] 161 [97–237] 193 [114–301] 224 [139–360] 24 [141–390]
Alcohol intake (g/d) 13 [6–31] 11 [3–24] 13 [6–25] 15 [6–34] 14 [7–32] 13 [6–32]
Data expressed as median [IQR] or n (%) unless otherwise stated
BMI body mass index, CKD chronic kidney disease, COPD common obstructive pulmonary disease, CVD cardiovascular disease, DKK Danish Krone, FA fatty acids, HRT hormone replacement therapy, IHD
ischemic heart disease, MET metabolic equivalent, NSAID Nonsteroidal anti-inflammatory drug, PAD peripheral artery disease
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indicate a threshold, with no added benefit observed beyond
500 mg/d in non-smokers and low alcohol consumers. We
demonstrate that inverse associations are strongest for current
smokers and individuals with high alcohol consumption, and that
a lower risk is seen for higher intakes in these groups.
The present study has many strengths including a large adult
population followed for 23 years with a plethora of participant
characteristics captured at baseline. Another strength is the lim-
ited loss to follow-up; all deaths and emigrations are captured in
the Danish registries. Furthermore, the data allowed us to adjust
for many potential dietary and lifestyle confounders and our
findings are strengthened with a falsification endpoint analysis,
which showed no association with total flavonoid intake. Despite
these strengths some limitations apply. As this is an observational
study, we are not able to infer causality. The possibility of fla-
vonoids being a marker of other unobserved and potentially
protective dietary factors cannot be discounted, although, in this
study the associations between total flavonoid intake and mor-
tality rates remained even after adjusting for other major indi-
cators of a healthy diet as well as within the highest tertile of total
fruit and vegetable intake. As dietary intake data were only cap-
tured at baseline, this may have changed over the 23 years of
follow-up. However, this misclassification would most likely have
attenuated the power to detect an association. Common FFQ
limitations apply in that not all flavonoid-rich foods, for example
berries, were captured. Furthermore, potential confounders were
only assessed at baseline; it is unclear how changes in the tra-
jectories of these confounders may have impacted upon the
observed associations. CVD- and cancer-related mortality
findings warrant further investigation as the Danish Register of
Causes of Death are based on clinical adjudication and are sus-
ceptible to misclassification bias. For this reason, we only used
broad definitions of cause-specific mortality10. Further caution
should be taken when extrapolating these findings to populations
outside of this cohort as the Danish population is more homo-
genous than many other countries; participants would most likely
have been Caucasian.
While previous studies have demonstrated that higher flavo-
noid intake is associated with a lower risk of all-cause mortality,
CVD mortality, and cancer mortality11,12, this is the first obser-
vational study to show that this association is present for all
subclasses after adjustment for lifestyle and dietary confounders.
This is likely attributable to our large cohort size, high number of
events, comprehensive estimation of flavonoid intake and high
prevalence of smoking and high alcohol consumption.
The theory, that there exists a threshold after which higher
intakes afford no added benefit is not new12,13. However, a critical
gap in our knowledge has been what intake of total and specific
flavonoids is required to achieve maximum benefit14. Results
from our study indicate that for total flavonoid intake, risk of all-
cause and CVD mortality was lower for flavonoid consumption
until intakes of approximately 500 mg/d, after which higher
intakes afforded no added benefit. This threshold was higher,
approximately 1000 mg/d for cancer-related mortality. That the
thresholds for each of the flavonoid subclasses approximately sum
to the threshold for total flavonoid intake is consistent with the
idea that all are important and afford added benefit. Interestingly,
these threshold levels exist well within daily dietary achievable
limits: one cup of tea, one apple, one orange, 100 g of blueberries,
and 100 g of broccoli would provide most of the flavonoid sub-
classes and over 500 mg of total flavonoids. In this population it is
likely that tea, chocolate, wine, apples, and pears were the main
food sources of flavonoids15.
We demonstrated that associations between intakes of flavo-
noids and both all-cause and cause-specific mortality were
stronger in current smokers and in those who consume, on
average, more than 20 g (two standard drinks) of alcohol per day.
In the Iowa Women’s Health Study there was evidence of an
inverse association between intakes the flavonol and flavanone
subclasses and all-cause mortality in ever-smokers, but not in
never-smokers16. Cigarette smoking17 and high alcohol con-
sumption (>2 standard drinks per day)18 are known to be car-
cinogenic and detrimental to endothelial function, blood pressure,
inflammation, nitric oxide bioavailability, blood lipids, platelet
function, and thrombosis. There is growing evidence from pre-
clinical and intervention studies that flavonoids have growth
inhibitory effects on various cancer cell types19 and that they may
ameliorate the above mentioned intermediate risk factors for
early mortality14,20,21. This may explain the stronger association
observed in smokers and heavy drinkers. Interestingly, and in
accordance with our results, a meta-analysis of flavonoid intake
showed an inverse association with smoking-related cancer inci-
dence22. The implications that dietary flavonoid intake may
partially mitigate harmful carcinogenic, metabolic, inflammatory,
and vascular effects of smoking and excess alcohol consumption
should not dissuade population health centers from anti-smoking
or alcohol awareness campaigns. Even with high flavonoid con-
sumption, these individuals remain at a much higher risk of early
mortality. Rather it should be used to inform future clinical trials
in these high-risk individuals and contribute to an optimization
of dietary guidelines in these high-risk populations, ensuring that
flavonoid intake is adequate and taking into consideration that
these populations may benefit from higher intakes. Conversely,
the inverse association between flavonoid intake and mortality
tended to be weaker in obese participants. These findings go
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Fig. 1 The association of total flavonoid intake with all-cause and cause-
specific mortality. Hazard ratios are based on Cox proportional hazards
models adjusted for age, sex, BMI, smoking status, physical activity, alcohol
intake, hypertension, hypercholesterolemia, social economic status
(income), and prevalent disease and are comparing the specific level of
flavonoid intake (horizontal axis) to the median intake for participants in
the lowest intake quintile
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against our a priori hypothesis that flavonoids would be more
protective in obese individuals as they have higher levels of
inflammation, oxidative stress, and vascular dysfunction. This is
difficult to interpret, as there is evidence that flavonoids impact
body composition23 but may be explained in part by gut micro-
biome composition. The gut microbiome plays a critical role in
flavonoid metabolism and therefore bioactivity24, and is dissim-
ilar in obese individuals25. Due to differences in baseline hazards
between obese and non-obese participants, these findings warrant
investigation on an absolute scale. In this Danish prospective
cohort study, we demonstrate that a moderate intake of flavo-
noids is inversely associated with all-cause, CVD-related, and
cancer-related mortality, with no added benefit seen for higher
intakes in non-smokers and low alcohol consumers. The stron-
gest associations observed between flavonoids and mortality was
in smokers and high alcohol consumers, with higher intakes
being more beneficial. These findings highlight the potential to
improve population health through dietary recommendations to
ensure adequate consumption of flavonoid-rich foods, particu-
larly in these high-risk populations.
Methods
Study population. From December 1993 to May 1997 the study recruited 56,468
participants without cancer prior to enrollment, between the age of 50–65 years,
residing in the greater area of Copenhagen and Aarhus, Denmark. Details of the
Danish Diet, Cancer, and Health cohort study, an associated cohort of the Eur-
opean Prospective Investigation into Nutrition and Cancer (EPIC), have been
published previously26. All Danish residents are provided with a unique and
permanent civil registration number enabling crosslinking between nationwide
registers and the Danish Diet, Cancer, and Health cohort on the individual level.
The following databases were crosslinked to the cohort: The Civil Registration
System which includes data on age, sex, and vital status; The Integrated Database
for Labor Market Research which contains information on annual income since
1980; The Danish Register of Causes of death with information on cause of death
since 1994 by International Classification of Diseases (ICD) codes; and The Danish
National Patient Register (DNPR) which holds information on all hospital
admissions in Denmark since 1978. All diagnoses were defined by ICD using the
8th revision (ICD-8) until 1993 and the 10th revision (ICD-10) since 1994.
Participants for whom information was missing or implausible (n= 215) and
those with extreme energy intakes [<2 092 kJ/day (<500 kcal/day) and >20 920 kJ/
day (>5000 kcal/day)] (n= 205), were excluded from the analysis (Fig. 4).
In Denmark, register studies do not require approval from ethics committees.
The Danish Data Protection Agency approved this study (Ref no 2012–58–0004 I-
Suite nr: 6357, VD-2018-117). Informed consent was obtained from all participants
to search for information from medical registries.
Dietary assessment. Dietary data were collected using a validated 192-item food-
frequency questionnaire, mailed out to participants prior to their baseline visit to
one of the two study centers27. Participants were asked to indicate their usual
frequency of intake of different food and beverage items over the past 12 months,
using a 12-category frequency scale that ranged from never to 8 times or more
per day. Details on the calculation of specific foods and nutrients have been
published previously26.
Exposures. The exposures of interest for this study were intakes of total flavonoids
and flavonoid subclasses. An estimate of the flavonoid content of each food and
beverage in the food-frequency questionnaire was derived from the Phenol-
Explorer database28. Correlations between levels of 12 flavonoids in 24-hr urine
samples and intake of their main food sources has been examined in 475 EPIC
subjects, showing significant correlations with their main food sources29. The effect
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Fig. 2 The association between flavonoid subclass intakes and all-cause mortality. Hazard ratios are based on Cox proportional hazards models adjusted for
age, sex, BMI, smoking status, physical activity, alcohol intake, hypertension, hypercholesterolemia, social economic status (income), and prevalent disease
and are comparing the specific level of flavonoid intake (horizontal axis) to the median intake for participants in the lowest intake quintile
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of food processing on flavonoid content was taken into consideration using
retention factors30. In the present study intakes of all flavonoids that were both
available in Phenol-Explorer and could be estimated from foods in the FFQ (n=
219) were used (Supplementary Table 5). These were grouped into 10 subclasses
according to their chemical structure [flavonols, flavanol monomers, flavanol oligo
+ polymers, flavanones, flavones, anthocyanins, isoflavones, dihydrochalcones,
dihydroflavonols and chalcones] by summing the intakes of all individual flavonoid
compounds within that flavonoid subclass (Supplementary Table 5). As the average
intakes of isoflavones, dihydrochalcones, dihydroflavonols and chalcones were very
low in this cohort (<5 mg/day), they were not included in the individual subclass
analyses. Total flavonoid intake was calculated by summing all 219 flavonoid
compounds. The content of flavonoids was expressed as aglycones in mg/100 g
fresh food weight.
Study outcomes. Vital status and date of death for every participant was obtained
from the Civil Registration System. Cause of death data was obtained from the
National Death Register. CVD-related mortality was defined as any ICD-10
diagnoses registered as a cause of death related to CVD (I00-I99) and cancer-
related mortality was defined as any ICD-10 diagnosis registered as a cause of death
related to cancer (C00-C99), dated after participant enrollment.
Table 2 Hazard ratios of all-cause mortality by quintiles of flavonoid intake
Q1 Q2 Q3 Q4 Q5
(n = 11 210) (n = 11 210) (n = 11 209) (n = 11 210) (n = 11 209)
Flavonols
No. events (%) 3 778 2 964 2 615 2 418 2 245
Intake (mg/d)a 14.8 (0.1–20.5) 25.9 (20.5–31.7) 38.5 (31.7–49.7) 66.0 (49.7–82.5) 115.9 (82.5–250.7)
HR (95% CI)
Model 1 ref. 0.79 (0.77, 0.82) 0.68 (0.66, 0.71) 0.64 (0.62, 0.67) 0.64 (0.61, 0.67)
Model 2 ref. 0.86 (0.84, 0.89) 0.80 (0.76, 0.83) 0.81 (0.78, 0.85) 0.83 (0.79, 0.87)
Model 3 ref. 0.89 (0.86, 0.92) 0.84 (0.80, 0.87) 0.87 (0.83, 0.91) 0.90 (0.86, 0.95)
Flavanol monomers
No. events (%) 3 748 2 887 2 764 2 420 2 264
Intake (mg/d)a 13.5 (0–20.5) 30.0 (20.5–45.3) 66.2 (45.3–115.2) 260.5 (115.2–281.4) 473.3 (281.4–916.3)
HR (95% CI)
Model 1 ref. 0.88 (0.86, 0.90) 0.73 (0.70, 0.76) 0.65 (0.62, 0.68) 0.66 (0.63, 0.69)
Model 2 ref. 0.93 (0.91, 0.94) 0.83 (0.80, 0.87) 0.85 (0.81, 0.89) 0.87 (0.83, 0.91)
Model 3 ref. 0.95 (0.93, 0.97) 0.88 (0.84, 0.93) 0.91 (0.87, 0.95) 0.93 (0.89, 0.97)
Flavanol oligo+ polymers
No. events (%) 3 680 2 969 2 633 2 510 2 291
Intake (mg/d)a 91 (0–136) 179 (136–217) 255 (217–302) 365 (302–434) 536 (360–2254)
HR (95% CI)
Model 1 ref. 0.75 (0.73, 0.78) 0.67 (0.64, 0.69) 0.65 (0.62, 0.68) 0.63 (0.60, 0.66)
Model 2 ref. 0.87 (0.84, 0.90) 0.82 (0.79, 0.85) 0.81 (0.78, 0.85) 0.81 (0.77, 0.84)
Model 3 ref. 0.90 (0.87, 0.93) 0.87 (0.83, 0.90) 0.87 (0.83, 0.91) 0.90 (0.86, 0.95)
Flavanones
No. events (%) 3 468 2 772 2 550 2 521 2 772
Intake (mg/d)a 3.4 (0–6.0) 9.3 (6.0–12.7) 17.5 (12.7–25.7) 32.0 (25.8–49.0) 70.1 (49.0–563.5)
HR (95% CI)
Model 1 ref. 0.83 (0.80, 0.85) 0.72 (0.69, 0.76) 0.73 (0.70, 0.76) 0.79 (0.76, 0.83)
Model 2 ref. 0.91 (0.88, 0.93) 0.85 (0.81, 0.89) 0.86 (0.82, 0.90) 0.91 (0.87, 0.96)
Model 3 ref. 0.92 (0.89, 0.95) 0.87 (0.83, 0.91) 0.88 (0.85, 0.92) 0.95 (0.9, 0.99)
Flavones
No. events (%) 3 457 2 835 2 560 2 456 2 775
Intake (mg/d)a 2.2 (0–3.0) 3.7 (3.0–4.5) 5.3 (4.5–6.1) 7.2 (6.1–8.8) 11.4 (8.8–50.6)
HR (95% CI)
Model 1 ref. 0.76 (0.74, 0.78) 0.67 (0.65, 0.70) 0.68 (0.65, 0.70) 0.73 (0.70, 0.76)
Model 2 ref. 0.88 (0.86, 0.91) 0.84 (0.81, 0.87) 0.85 (0.81, 0.88) 0.89 (0.85, 0.94)
Model 3 ref. 0.90 (0.87, 0.92) 0.86 (0.83, 0.90) 0.88 (0.84, 0.92) 0.95 (0.90, 1.00)
Anthocyanins
No. events (%) 3 599 2 521 2 426 2 693 2 844
Intake (mg/d)a 5.2 (0–9.6) 12.5 (9.6–16.9) 20.0 (16.9–24.4) 35.7 (24.4–53.2) 70.7 (53.2–396.9)
HR (95% CI)
Model 1 ref. 0.71 (0.69, 0.74) 0.63 (0.60, 0.65) 0.69 (0.66, 0.72) 0.80 (0.77, 0.84)
Model 2 ref. 0.84 (0.81, 0.87) 0.78 (0.75, 0.82) 0.80 (0.77, 0.84) 0.83 (0.79, 0.87)
Model 3 ref. 0.85 (0.82, 0.88) 0.80 (0.77, 0.84) 0.82 (0.79, 0.86) 0.86 (0.82, 0.90)
Total flavonoids
No. events (%) 3 706 2 900 2 728 2 455 2 294
Intake (mg/d)a 173.0 (5.6–250.8) 320.2 (250.8–394.0) 494.3 (394.1–601.2) 725.9 (601.2–908.4) 1201.3 (908.5–3552.0)
HR (95% CI)
Model 1 ref. 0.78 (0.76, 0.81) 0.68 (0.65, 0.71) 0.66 (0.63, 0.69) 0.64 (0.61, 0.67)
Model 2 ref. 0.88 (0.85, 0.91) 0.83 (0.80, 0.86) 0.83 (0.80, 0.87) 0.83 (0.80, 0.87)
Model 3 ref. 0.91 (0.88, 0.94) 0.88 (0.84, 0.91) 0.90 (0.86, 0.94) 0.92 (0.88, 0.97)
Hazard ratios (95% CI) for 23-year all-cause mortality obtained from restricted cubic splines based on Cox proportional hazards models. Model 1 adjusted for age and sex; Model 2 adjusted for age, sex,
BMI, smoking status, physical activity, alcohol intake, hypertension, hypercholesterolemia, social economic status (income), diabetes, and prevalent disease; Model 3 adjusted for all covariates in Model 2
plus intakes of fish, red meat, processed meat, dietary fiber, polyunsaturated fatty acids, monounsaturated fatty acids, and saturated fatty acids
aMedian; range in parentheses (all such values)
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Covariates. Information on sex, age, and lifestyle factors such as smoking, alcohol
consumption, and daily activity were obtained using the self-administered ques-
tionnaire at study enrollment. Clinical measurements such as BMI and total
cholesterol were taken at the study centers. Annual income was used as a proxy for
socio-economic status and was defined as household income after taxation and
interest, for the value of the Danish currency in 2015. Income, grouped in quartiles,
was estimated as the mean income of 5 years up to and including the year of study
inclusion. Self-reported myocardial infarction and self-reported stroke at baseline
were combined with ICD codes (Supplementary Table 6) of ischemic heart disease
and ischemic stroke, respectively, dated prior to participant enrollment. ICD codes
dated prior to participant enrollment were used to identify baseline comorbidities
of peripheral artery disease, chronic kidney disease (CKD), chronic obstructive
pulmonary disease (COPD), heart failure, atrial fibrillation, and cancers
(Supplementary Table 6). For hypertension and diabetes mellitus, only self-
reported prevalence was used due to the low validity of ICD codes in the DNPR31.
Prevalent CVD was defined by the presence of at least one diagnosis of ischemic
heart disease, peripheral artery disease, ischemic stroke, heart failure, or atrial
fibrillation prior to recruitment.
Statistical analysis. Participants were followed for a maximum of 23 years, from
the date of enrollment until the date of death, emigration, or end of follow-up
(August, 2017), whichever came first. The exposure variables (total flavonoid and
flavonoid subclass intakes) were categorized by quintiles of intake (20% of parti-
cipants from the total study population in each). Correlations between flavonoid
subclasses were examined using Pearsons’ correlation coefficients.
Table 3 Hazard ratios of cardiovascular disease-related mortality by quintiles of flavonoid intake
Q1 Q2 Q3 Q4 Q5
Flavonols
No. events (%) 1 112 844 712 689 624
Intake (mg/d)a 14.8 (0.1–20.5) 25.9 (20.5–31.7) 38.5 (31.7–49.7) 66.0 (49.7–82.5) 115.9 (82.5–250.7)
HR (95% CI)
Model 1 ref. 0.76 (0.73, 0.80) 0.64 (0.60, 0.69) 0.62 (0.57, 0.67) 0.62 (0.56, 0.67)
Model 2 ref. 0.84 (0.80, 0.88) 0.77 (0.71, 0.83) 0.82 (0.76, 0.89) 0.85 (0.78, 0.93)
Model 3 ref. 0.88 (0.83, 0.93) 0.84 (0.77, 0.91) 0.91 (0.83, 0.99) 0.95 (0.87, 1.05)
Flavanol monomers
No. events (%) 1 082 821 791 669 618
Intake (mg/d)a 13.5 (0–20.5) 30.0 (20.5–45.3) 66.2 (45.3–115.2) 260.5 (115.2–281.4) 473.3 (281.4–916.3)
HR (95% CI)
Model 1 ref. 0.87 (0.84, 0.91) 0.72 (0.66, 0.78) 0.64 (0.59, 0.70) 0.64 (0.59, 0.70)
Model 2 ref. 0.92 (0.89, 0.96) 0.82 (0.76, 0.90) 0.88 (0.81, 0.96) 0.90 (0.82, 0.98)
Model 3 ref. 0.95 (0.92, 0.99) 0.90 (0.82, 0.98) 0.95 (0.87, 1.04) 0.97 (0.89, 1.06)
Flavanol oligo+ polymers
No. events (%) 1 050 849 743 718 621
Intake (mg/d)a 91 (0–136) 179 (136–217) 255 (217–302) 365 (302–434) 536 (360–2254)
HR (95% CI)
Model 1 ref. 0.74 (0.69, 0.78) 0.65 (0.61, 0.70) 0.64 (0.59, 0.69) 0.61 (0.56, 0.66)
Model 2 ref. 0.87 (0.82, 0.92) 0.83 (0.77, 0.89) 0.82 (0.76, 0.89) 0.82 (0.75, 0.89)
Model 3 ref. 0.91 (0.85, 0.97) 0.89 (0.82, 0.95) 0.90 (0.83, 0.98) 0.94 (0.85, 1.03)
Flavanones
No. events (%) 975 774 751 664 817
Intake (mg/d)a 3.4 (0–6.0) 9.3 (6.0–12.7) 17.5 (12.7–25.7) 32.0 (25.8–49.0) 70.1 (49.0–563.5)
HR (95% CI)
Model 1 ref. 0.83 (0.78, 0.87) 0.72 (0.66, 0.78) 0.71 (0.66, 0.77) 0.79 (0.73, 0.86)
Model 2 ref. 0.91 (0.86, 0.96) 0.85 (0.77, 0.92) 0.85 (0.78, 0.92) 0.92 (0.84, 1.00)
Model 3 ref. 0.93 (0.88, 0.98) 0.88 (0.81, 0.96) 0.89 (0.82, 0.96) 0.96 (0.88, 1.05)
Flavones
No. events (%) 956 823 676 720 806
Intake (mg/d)a 2.2 (0–3.0) 3.7 (3.0–4.5) 5.3 (4.5–6.1) 7.2 (6.1–8.8) 11.4 (8.8–50.6)
HR (95% CI)
Model 1 ref. 0.76 (0.71, 0.80) 0.67 (0.62, 0.72) 0.68 (0.63, 0.73) 0.74 (0.68, 0.81)
Model 2 ref. 0.89 (0.84, 0.95) 0.85 (0.79, 0.92) 0.86 (0.80, 0.93) 0.92 (0.85, 1.00)
Model 3 ref. 0.91 (0.85, 0.96) 0.87 (0.81, 0.94) 0.89 (0.82, 0.97) 0.97 (0.88, 1.06)
Anthocyanins
No. events (%) 1 051 694 683 769 784
Intake (mg/d)a 5.2 (0–9.6) 12.5 (9.6–16.9) 20.0 (16.9–24.4) 35.7 (24.4–53.2) 70.7 (53.2–396.9)
HR (95% CI)
Model 1 ref. 0.67 (0.63, 0.71) 0.58 (0.54, 0.63) 0.66 (0.61, 0.72) 0.77 (0.71, 0.84)
Model 2 ref. 0.81 (0.76, 0.86) 0.75 (0.70, 0.82) 0.81 (0.74, 0.87) 0.83 (0.76, 0.91)
Model 3 ref. 0.85 (0.80, 0.91) 0.81 (0.75, 0.88) 0.86 (0.79, 0.94) 0.90 (0.82, 0.99)
Total flavonoids
No. events (%) 1 062 818 773 710 618
Intake (mg/d)a 173.0 (5.6–250.8) 320.2 (250.8–394.0) 494.3 (394.1–601.2) 725.9 (601.2–908.4) 1201.3 (908.5–3552.0)
HR (95% CI)
Model 1 ref. 0.77 (0.73, 0.82) 0.67 (0.62, 0.72) 0.66 (0.61, 0.71) 0.62 (0.57, 0.67)
Model 2 ref. 0.88 (0.83, 0.93) 0.84 (0.78, 0.90) 0.87 (0.80, 0.94) 0.85 (0.78, 0.93)
Model 3 ref. 0.92 (0.87, 0.98) 0.91 (0.84, 0.98) 0.96 (0.88, 1.04) 0.97 (0.88, 1.06)
Hazard ratios (95% CI) for 23-year cardiovascular disease-related mortality, in participants without cardiovascular disease at baseline (n= 52 492), obtained from restricted cubic splines based on Cox
proportional hazards models. Model 1 adjusted for age and sex; Model 2 adjusted for age, sex, BMI, smoking status, physical activity, alcohol intake, hypertension, hypercholesterolemia, social economic
status (income), diabetes, and prevalent disease; Model 3 adjusted for all covariates in Model 2 plus intakes of fish, red meat, processed meat, dietary fiber, polyunsaturated fatty acids, monounsaturated
fatty acids, and saturated fatty acids
aMedian; range in parentheses (all such values)
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Potential nonlinear relationships were examined using restricted cubic
splines, with hazard ratios (HRs) based on Cox proportional hazards models.
HRs with 95% confidence intervals (CIs) were plotted for each unit of the
exposure against the median intake in quintile 1. In all spline analyses, the
exposure variables were treated as continuous and individuals with intakes more
than four standard deviations above the mean were excluded. The test of
nonlinearity used analysis of variance to compare the model with only the linear
term to the model that included both the linear and the cubic spline terms. HRs
and 95% CIs for the median intakes in each quintile of the exposure variables
were obtained from the splines. Cox proportional hazards assumptions were
tested using log-log plots of the survival function vs. time and assessed for
parallel appearance. As our aim was to obtain relative estimates for risk factors,
deaths from causes other than the outcome of interest were censored rather than
treated as a competing risk32. Three models of adjustment were used: (1) age and
sex; (2) age, sex, BMI, smoking status, physical activity (total daily metabolic
equivalent), pure alcohol intake (g/d), hypertension (yes/no),
hypercholesterolemia (yes/no), social economic status (income), and prevalent
disease (diabetes, CVD, COPD, CKD and cancer, entered into the model
separately); (3) model 2 plus intakes (g/d) of fish, red meat, processed meat,
dietary fiber, polyunsaturated fatty acids, monounsaturated fatty acids and
saturated fatty acids. Covariates were chosen a priori to the best of our
knowledge of potential confounders of flavonoid intake and mortality. As some
covariates in model 2 (hypertension, hypercholesterolemia and prevalent
diseases) are potentially on the causal pathway and therefore introduce collider
stratification bias, we removed them in a sensitivity analysis. When investigating
CVD-related mortality we excluded participants with CVD at baseline. Using
Table 4 Hazard ratios of cancer-related mortality by quintiles of flavonoid intake
Q1 Q2 Q3 Q4 Q5
Flavonols
No. events (%) 1 641 1 312 1 216 1 137 993
Intake (mg/d)a 14.8 (0.1–20.5) 25.9 (20.5–31.7) 38.5 (31.7–49.7) 66.0 (49.7–82.5) 115.9 (82.5–250.7)
HR (95% CI)
Model 1 ref. 0.79 (0.75, 0.83) 0.71 (0.67, 0.75) 0.67 (0.63, 0.72) 0.64 (0.60, 0.69)
Model 2 ref. 0.89 (0.85, 0.93) 0.83 (0.78, 0.88) 0.82 (0.77, 0.88) 0.81 (0.75, 0.87)
Model 3 ref. 0.92 (0.88, 0.97) 0.88 (0.83, 0.95) 0.89 (0.83, 0.95) 0.88 (0.81, 0.95)
Flavanol monomers
No. events (%) 1 650 1 338 1 198 1 093 1 020
Intake (mg/d)a 13.5 (0–20.5) 30.0 (20.5–45.3) 66.2 (45.3–115.2) 260.5 (115.2–281.4) 473.3 (281.4–916.3)
HR (95% CI)
Model 1 ref. 0.88 (0.86, 0.91) 0.73 (0.69, 0.78) 0.66 (0.62, 0.70) 0.65 (0.61, 0.69)
Model 2 ref. 0.92 (0.89, 0.95) 0.82 (0.77, 0.88) 0.83 (0.78, 0.89) 0.83 (0.77, 0.89)
Model 3 ref. 0.95 (0.92, 0.98) 0.88 (0.82, 0.94) 0.88 (0.82, 0.94) 0.88 (0.82, 0.94)
Flavanol oligo+ polymers
No. events (%) 1 594 1 346 1 209 1 119 1 031
Intake (mg/d)a 91 (0–136) 179 (136–217) 255 (217–302) 365 (302–434) 536 (360–2254)
HR (95% CI)
Model 1 ref. 0.79 (0.75, 0.83) 0.71 (0.67, 0.75) 0.67 (0.63, 0.72) 0.64 (0.60, 0.69)
Model 2 ref. 0.90 (0.85, 0.94) 0.85 (0.80, 0.90) 0.81 (0.76, 0.87) 0.79 (0.74, 0.85)
Model 3 ref. 0.92 (0.88, 0.97) 0.88 (0.83, 0.94) 0.86 (0.80, 0.92) 0.86 (0.80, 0.93)
Flavanones
No. events (%) 1 521 1 299 1 170 1 145 1 164
Intake (mg/d)a 3.4 (0–6.0) 9.3 (6.0–12.7) 17.5 (12.7–25.7) 32.0 (25.8–49.0) 70.1 (49.0–563.5)
HR (95% CI)
Model 1 ref. 0.86 (0.82, 0.89) 0.76 (0.71, 0.81) 0.73 (0.69, 0.78) 0.75 (0.70, 0.80)
Model 2 ref. 0.91 (0.78, 0.95) 0.84 (0.78, 0.90) 0.82 (0.77, 0.87) 0.83 (0.77, 0.88)
Model 3 ref. 0.92 (0.88, 0.97) 0.87 (0.81, 0.93) 0.84 (0.79, 0.90) 0.85 (0.79, 0.91)
Flavones
No. events (%) 1 532 1 293 1 184 1 093 1 197
Intake (mg/d)a 2.2 (0–3.0) 3.7 (3.0–4.5) 5.3 (4.5–6.1) 7.2 (6.1–8.8) 11.4 (8.8–50.6)
HR (95% CI)
Model 1 ref. 0.79 (0.75, 0.82) 0.69 (0.66, 0.73) 0.68 (0.64, 0.72) 0.71 (0.67, 0.76)
Model 2 ref. 0.88 (0.84, 0.92) 0.82 (0.78, 0.87) 0.81 (0.76, 0.86) 0.84 (0.78, 0.90)
Model 3 ref. 0.88 (0.84, 0.92) 0.83 (0.78, 0.88) 0.82 (0.77, 0.87) 0.85 (0.79, 0.92)
Anthocyanins
No. events (%) 1 538 1 176 1 124 1 215 1 246
Intake (mg/d)a 5.2 (0–9.6) 12.5 (9.6–16.9) 20.0 (16.9–24.4) 35.7 (24.4–53.2) 70.7 (53.2–396.9)
HR (95% CI)
Model 1 ref. 0.76 (0.73, 0.80) 0.69 (0.65, 0.74) 0.76 (0.71, 0.81) 0.83 (0.78, 0.89)
Model 2 ref. 0.87 (0.83, 0.91) 0.82 (0.77, 0.87) 0.83 (0.78, 0.89) 0.83 (0.78, 0.90)
Model 3 ref. 0.91 (0.86, 0.96) 0.88 (0.82, 0.94) 0.89 (0.83, 0.96) 0.90 (0.83, 0.97)
Total flavonoids
No. events (%) 1 607 1 348 1 240 1 083 1 021
Intake (mg/d)a 173.0 (5.6–250.8) 320.2 (250.8–394.0) 494.3 (394.1–601.2) 725.9 (601.2–908.4) 1201.3 (908.5–3552.0)
HR (95% CI)
Model 1 ref. 0.81 (0.78, 0.85) 0.71 (0.67, 0.75) 0.67 (0.63, 0.71) 0.64 (0.59, 0.68)
Model 2 ref. 0.90 (0.86, 0.94) 0.84 (0.79, 0.89) 0.81 (0.76, 0.87) 0.80 (0.74, 0.85)
Model 3 ref. 0.93 (0.88, 0.97) 0.88 (0.83, 0.94) 0.86 (0.80, 0.92) 0.86 (0.80, 0.93)
Hazard ratios (95% CI) for 23-year cancer-related mortality, in participants without cancer at baseline (n= 55 801), obtained from restricted cubic splines based on Cox proportional hazards models.
Model 1 adjusted for age and sex; Model 2 adjusted for age, sex, BMI, smoking status, physical activity, alcohol intake, hypertension, hypercholesterolemia, social economic status (income), diabetes, and
prevalent disease; Model 3 adjusted for all covariates in Model 2 plus intakes of fish, red meat, processed meat, dietary fiber, polyunsaturated fatty acids, monounsaturated fatty acids, and saturated
fatty acids
aMedian; range in parentheses (all such values)
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ICD-8 codes, we identified an additional 247 participants with a diagnosis of
cancer prior to enrollment; when investigating cancer-related mortality we
excluded these participants (Fig. 4).
We stratified our analyses by sex, BMI, smoking history, alcohol intake, physical
activity, and prevalent diabetes to test for potential effect modification. When
stratifying by alcohol intake and BMI, we excluded all participants with an alcohol
intake of zero (n= 1 298) and a BMI < 18.5 (n= 453) respectively, as these were
not our subgroups of interest. We chose stratification cut-off points of 20 g pure
alcohol per day, corresponding to 2 standard drinks, and a BMI of 30 kg/m2 as the
risk of mortality is highest beyond these levels18,33. A further subgroup
‘dose–response’ analysis was performed by pack-years of smoking, alcohol intake
and BMI categories.
To account for the possibility of differing dietary habits in those at a high risk of
death, we repeated our primary analysis after excluding participants with prevalent
diabetes, CVD, COPD, CKD, and cancer. As we believe crude values of flavonoid
intake to be more relevant than energy-adjusted values, we did not include total
energy intake as a covariate in any model. However, energy intake was added to
model 2 in a sensitivity analysis to assess its impact on the association between
flavonoid intake and all-cause mortality. To determine whether the associations
between flavonoid intake and all-cause mortality were independent of fruit and
vegetable consumption, we stratified the analysis by tertiles of total fruit and
vegetable intake. In order to assess the likelihood of confounding we used a
falsification endpoint which we considered unlikely to be causally affected by
flavonoid intake; any emergency, inpatient, or outpatient visit for a burn or foreign
object (Supplementary Table 6). Analyses were undertaken using STATA/IC 14.2
(StataCorp LLC) and R statistics (R Core Team34). Statistical significance was set at
p ≤ 0.05 (two-tailed) for all tests.
Role of funding source. The funding source had no role in study design, pre-
paration of this manuscript, or decision to submit the paper for publication.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Due to restrictions related to Danish law and protecting patient privacy, the combined set
of data as used in this study can only be made available through a trusted third party,
Statistics Denmark. This state organization holds the data used for this study. University-
based Danish scientific organizations can be authorized to work with data within
Statistics Denmark and such organization can provide access to individual scientists
inside and outside of Denmark. Requests for data may be sent to Statistics Denmark:
https://www.dst.dk/en/kontakt or the Danish Data Protection Agency: https://www.
datatilsynet.dk/english.
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